Literature DB >> 20026646

CDC73/HRPT2 CpG island hypermethylation and mutation of 5'-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors.

Michael A Hahn1, Viive M Howell, Anthony J Gill, Adele Clarkson, Graham Weaire-Buchanan, Bruce G Robinson, Leigh Delbridge, Oliver Gimm, Wolfgang D Schmitt, Bin T Teh, Deborah J Marsh.   

Abstract

The tumor suppressor HRPT2/CDC73 is mutated in constitutive DNA from patients with the familial disorder hyperparathyroidism-jaw tumor syndrome and in approximately 70% of all parathyroid carcinomas. In a number of HRPT2 mutant tumors however, expression of the encoded protein parafibromin is lost in the absence of a clear second event such as HRPT2 allelic loss or the presence of a second mutation in this tumor suppressor gene. We sought to determine whether hypermethylation of a 713 bp CpG island extending 648 nucleotides upstream of the HRPT2 translational start site and 65 nucleotides into exon 1 might be a mechanism contributing to the loss of expression of parafibromin in parathyroid tumors. Furthermore, we asked whether mutations might be present in the 5'-untranslated region (5'-UTR) of HRPT2. We investigated a pool of tissue from 3 normal parathyroid glands, as well as 15 individual parathyroid tumor samples including 6 tumors with known HRPT2 mutations, for hypermethylation of the HRPT2 CpG island. Methylation was not identified in any specimens despite complete loss of parafibromin expression in two parathyroid carcinomas with a single detectable HRPT2 mutation and retention of the wild-type HRPT2 allele. Furthermore, no mutations of a likely pathogenic nature were identified in the 5'-UTR of HRPT2. These data strongly suggest that alternative mechanisms such as mutation in HRPT2 intronic regions, additional epigenetic regulation such as histone modifications, or other regulatory inactivation mechanisms such as targeting by microRNAs may play a role in the loss of parafibromin expression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20026646     DOI: 10.1677/ERC-09-0291

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  17 in total

1.  Genome-wide analysis of differentially expressed lncRNA in sporadic parathyroid tumors.

Authors:  T Jiang; B J Wei; D X Zhang; L Li; G L Qiao; X A Yao; Z W Chen; X Liu; X Y Du
Journal:  Osteoporos Int       Date:  2019-04-10       Impact factor: 4.507

2.  Oncogenic microRNA-155 down-regulates tumor suppressor CDC73 and promotes oral squamous cell carcinoma cell proliferation: implications for cancer therapeutics.

Authors:  Mohammad Iqbal Rather; Mathighatta N Nagashri; Shivananda S Swamy; Kodaganur S Gopinath; Arun Kumar
Journal:  J Biol Chem       Date:  2012-11-19       Impact factor: 5.157

Review 3.  Parathyroid cancer.

Authors:  John M Sharretts; Electron Kebebew; William F Simonds
Journal:  Semin Oncol       Date:  2010-12       Impact factor: 4.929

4.  Transcriptional repression of tumor suppressor CDC73, encoding an RNA polymerase II interactor, by Wilms tumor 1 protein (WT1) promotes cell proliferation: implication for cancer therapeutics.

Authors:  Mohammad Iqbal Rather; Shivananda Swamy; Kodaganur S Gopinath; Arun Kumar
Journal:  J Biol Chem       Date:  2013-11-20       Impact factor: 5.157

Review 5.  Diagnosis and management of parathyroid cancer.

Authors:  Klaus-Martin Schulte; Nadia Talat
Journal:  Nat Rev Endocrinol       Date:  2012-07-03       Impact factor: 43.330

Review 6.  Overview of the 2022 WHO Classification of Parathyroid Tumors.

Authors:  Lori A Erickson; Ozgur Mete; C Christofer Juhlin; Aurel Perren; Anthony J Gill
Journal:  Endocr Pathol       Date:  2022-02-17       Impact factor: 3.943

Review 7.  Primary hyperparathyroidism.

Authors:  John P Bilezikian; Natalie E Cusano; Aliya A Khan; Jian-Min Liu; Claudio Marcocci; Francisco Bandeira
Journal:  Nat Rev Dis Primers       Date:  2016-05-19       Impact factor: 52.329

8.  Global and gene-specific promoter methylation analysis in primary hyperparathyroidism.

Authors:  Luqman Sulaiman; C Christofer Juhlin; Inga-Lena Nilsson; Omid Fotouhi; Catharina Larsson; Jamileh Hashemi
Journal:  Epigenetics       Date:  2013-06-13       Impact factor: 4.528

9.  Genome-wide and locus specific alterations in CDC73/HRPT2-mutated parathyroid tumors.

Authors:  Luqman Sulaiman; Felix Haglund; Jamileh Hashemi; Takao Obara; Jörgen Nordenström; Catharina Larsson; C Christofer Juhlin
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

10.  Novel HRPT2/CDC73 gene mutations and loss of expression of parafibromin in Chinese patients with clinically sporadic parathyroid carcinomas.

Authors:  Ou Wang; Chunyan Wang; Min Nie; Quancai Cui; Heng Guan; Yan Jiang; Mei Li; Weibo Xia; Xunwu Meng; Xiaoping Xing
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.